Adma Biologics Inc (ADMA)

$6.46

-0.08

(-1.22%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Adma Biologics Inc

  • Increasing Revenue

    Revenue is up for the last 15 quarters, 7.78M → 73.90M (in $), with an average increase of 14.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.56M → -17.64M (in $), with an average decrease of 787.9% per quarter

Performance

  • $6.43
    $6.53
    $6.46
    downward going graph

    0.46%

    Downside

    Day's Volatility :1.53%

    Upside

    1.07%

    downward going graph
  • $3.06
    $6.76
    $6.46
    downward going graph

    52.63%

    Downside

    52 Weeks Volatility :54.73%

    Upside

    4.44%

    downward going graph

Returns

PeriodAdma Biologics IncSector (Health Care)Index (Russel 2000)
3 Months
27.17%
1.7%
0.0%
6 Months
103.79%
11.3%
0.0%
1 Year
93.99%
5.4%
1.3%
3 Years
218.23%
13.9%
-22.1%

Highlights

Market Capitalization
1.5B
Book Value
$0.6
Earnings Per Share (EPS)
-0.13
PEG Ratio
0.0
Wall Street Target Price
8.38
Profit Margin
-10.94%
Operating Margin TTM
19.26%
Return On Assets TTM
4.51%
Return On Equity TTM
-19.67%
Revenue TTM
258.2M
Revenue Per Share TTM
1.15
Quarterly Revenue Growth YOY
47.9%
Gross Profit TTM
35.3M
EBITDA
32.8M
Diluted Eps TTM
-0.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.3
EPS Estimate Next Year
0.5
EPS Estimate Current Quarter
0.02
EPS Estimate Next Quarter
0.04

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Adma Biologics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 29.72%

Current $6.46
Target $8.38

Company Financials

FY18Y/Y Change
Revenue
17.0M
↓ 25.37%
Net Income
-65.7M
↑ 50.24%
Net Profit Margin
-387.06%
↓ 194.8%
FY19Y/Y Change
Revenue
29.3M
↑ 72.79%
Net Income
-57.0M
↓ 13.23%
Net Profit Margin
-194.37%
↑ 192.69%
FY20Y/Y Change
Revenue
42.2M
↑ 43.85%
Net Income
-87.6M
↑ 53.57%
Net Profit Margin
-207.5%
↓ 13.13%
FY21Y/Y Change
Revenue
80.9M
↑ 91.72%
Net Income
-84.5M
↓ 3.6%
Net Profit Margin
-104.34%
↑ 103.16%
FY22Y/Y Change
Revenue
154.1M
↑ 90.36%
Net Income
-85.2M
↑ 0.86%
Net Profit Margin
-55.29%
↑ 49.05%
FY23Y/Y Change
Revenue
258.2M
↑ 67.59%
Net Income
-28.2M
↓ 66.85%
Net Profit Margin
-10.94%
↑ 44.35%
Q3 FY22Q/Q Change
Revenue
41.1M
↑ 21.19%
Net Income
-20.5M
↑ 11.59%
Net Profit Margin
-49.85%
↑ 4.29%
Q4 FY22Q/Q Change
Revenue
50.0M
↑ 21.64%
Net Income
-25.9M
↑ 26.6%
Net Profit Margin
-51.88%
↓ 2.03%
Q1 FY23Q/Q Change
Revenue
56.9M
↑ 13.87%
Net Income
-12.8M
↓ 50.78%
Net Profit Margin
-22.43%
↑ 29.45%
Q2 FY23Q/Q Change
Revenue
60.1M
↑ 5.64%
Net Income
-6.4M
↓ 50.09%
Net Profit Margin
-10.6%
↑ 11.83%
Q3 FY23Q/Q Change
Revenue
67.3M
↑ 11.89%
Net Income
2.6M
↓ 140.26%
Net Profit Margin
3.81%
↑ 14.41%
Q4 FY23Q/Q Change
Revenue
73.9M
↑ 9.85%
Net Income
-17.6M
↓ 787.88%
Net Profit Margin
-23.88%
↓ 27.69%
FY18Y/Y Change
Total Assets
88.9M
↓ 17.72%
Total Liabilities
69.1M
↑ 2.1%
FY19Y/Y Change
Total Assets
127.1M
↑ 43.0%
Total Liabilities
100.9M
↑ 46.0%
FY20Y/Y Change
Total Assets
207.7M
↑ 63.41%
Total Liabilities
119.4M
↑ 18.36%
FY21Y/Y Change
Total Assets
276.3M
↑ 33.02%
Total Liabilities
135.1M
↑ 13.11%
FY22Y/Y Change
Total Assets
348.5M
↑ 26.14%
Total Liabilities
196.5M
↑ 45.46%
FY23Y/Y Change
Total Assets
329.2M
↓ 5.53%
Total Liabilities
194.0M
↓ 1.28%
Q3 FY22Q/Q Change
Total Assets
300.6M
↑ 1.22%
Total Liabilities
200.2M
↑ 9.66%
Q4 FY22Q/Q Change
Total Assets
348.5M
↑ 15.94%
Total Liabilities
196.5M
↓ 1.84%
Q1 FY23Q/Q Change
Total Assets
340.8M
↓ 2.2%
Total Liabilities
195.1M
↓ 0.69%
Q2 FY23Q/Q Change
Total Assets
343.0M
↑ 0.66%
Total Liabilities
196.3M
↑ 0.58%
Q3 FY23Q/Q Change
Total Assets
349.0M
↑ 1.74%
Total Liabilities
197.6M
↑ 0.66%
Q4 FY23Q/Q Change
Total Assets
329.2M
↓ 5.68%
Total Liabilities
194.0M
↓ 1.81%
FY18Y/Y Change
Operating Cash Flow
-62.7M
↑ 68.17%
Investing Cash Flow
-2.1M
↓ 113.77%
Financing Cash Flow
42.9M
↓ 29.35%
FY19Y/Y Change
Operating Cash Flow
-76.2M
↑ 21.56%
Investing Cash Flow
-3.8M
↑ 81.9%
Financing Cash Flow
80.0M
↑ 86.39%
FY20Y/Y Change
Operating Cash Flow
-102.0M
↑ 33.87%
Investing Cash Flow
-12.7M
↑ 233.82%
Financing Cash Flow
143.9M
↑ 79.86%
FY21Y/Y Change
Operating Cash Flow
-112.4M
↑ 10.16%
Investing Cash Flow
-13.5M
↑ 6.18%
Financing Cash Flow
121.0M
↓ 15.88%
FY22Y/Y Change
Operating Cash Flow
-59.5M
↓ 47.04%
Investing Cash Flow
-13.9M
↑ 2.96%
Financing Cash Flow
108.9M
↓ 10.08%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.3M
↑ 3.54%
Investing Cash Flow
-3.4M
↓ 14.2%
Financing Cash Flow
-843.8K
↑ 164.48%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.4M
↓ 44.45%
Investing Cash Flow
-3.7M
↑ 10.89%
Financing Cash Flow
62.7M
↓ 7535.89%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.7M
↑ 99.51%
Investing Cash Flow
-1.9M
↓ 48.12%
Financing Cash Flow
-650.5K
↓ 101.04%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.1M
↓ 58.85%
Investing Cash Flow
-872.6K
↓ 55.13%
Financing Cash Flow
240.1K
↓ 136.91%

Technicals Summary

Sell

Neutral

Buy

Adma Biologics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adma Biologics Inc
Adma Biologics Inc
1.1%
103.79%
93.99%
218.23%
218.23%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adma Biologics Inc
Adma Biologics Inc
NA
NA
0.0
0.3
-0.2
0.05
NA
0.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adma Biologics Inc
Adma Biologics Inc
Buy
$1.5B
218.23%
NA
-10.94%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • BlackRock Inc

    7.85%

  • Vanguard Group Inc

    5.65%

  • Nuveen Asset Management, LLC

    4.98%

  • State Street Corporation

    4.16%

  • Stonepine Capital Management Llc

    4.04%

  • D. E. Shaw & Co LP

    3.32%

Company Information

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Organization
Adma Biologics Inc
Employees
624
CEO
Mr. Adam S. Grossman
Industry
Health Technology

Discover More

FAQs